Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry.
Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry.
复制标题
放射性标记抗体疗法的放射生物学应用于肿瘤剂量测定。
DOI：
10.1118/1.597055
复制
发表时间：
1993
期刊：
影响因子：
3.8
通讯作者：
Wong,JY
中科院分区：
文献类型：
--
作者：
Langmuir,VK;Fowler,JF;Knox,SJ;Wessels,BW;Sutherland,RM;Wong,JY
本文综述了放射性标记抗体的放射免疫治疗（RIT）的放射生物学方面，包括RIT和外照射之间的比较。辐射杀死细胞的有效性随着剂量率而降低，并且降低的速率由辐射存活曲线上肩部的大小决定。修复能力差的肿瘤比修复能力好的肿瘤表现出更少的剂量率效应。治疗期间肿瘤细胞的持续增殖发生在非常低的剂量率下，并可能导致低剂量率辐射的有效性降低。对正常组织的毒性将决定可给予的放射性标记抗体的总剂量，这将受到放射性核素和抗体选择的影响。报告的RIT有效性增强可能是由于多种因素，包括选择性靶向负责肿瘤体积倍增的细胞、肿瘤表面结合而不是整个肿瘤体积的均匀结合、靶向肿瘤血管系统或阻断G2中的细胞周期进展。在RIT期间，缺氧肿瘤细胞的再氧合时间比常规外射束放射治疗期间更少。尚未确定这是否会对RIT产生不利影响。RIT成功的最重要因素可能是剂量异质性。肿瘤的任何未被靶向且未接受显著辐射剂量的存活部分都可能导致治疗失败，无论肿瘤的其余部分接受的剂量有多高。RIT和外部光束辐射之间的比较显示了广泛的相对功效。最有可能对RIT产生反应的肿瘤是修复能力差的肿瘤、在细胞周期的放射敏感期易受阻断的肿瘤、快速恢复的肿瘤和均匀表达相关抗原的肿瘤。从放射生物学的角度来看，似乎RIT单独不太可能治愈许多肿瘤，与其他治疗方式相结合将是必不可少的。
This paper reviews the radiobiological aspects of radioimmunotherapy (RIT) with radiolabeled antibodies, including comparisons between RIT and external beam irradiation. The effectiveness of cell killing by radiation decreases with the dose rate and the rate of decrease is determined by the size of the shoulder on the radiation survival curve. Tumors with poor repair capabilities exhibit less of a dose rate effect than tumors with good repair capabilities. Continued tumor cell proliferation during treatment occurs at very low dose rates and can contribute to the reduced effectiveness of low dose rate radiation. Toxicity to normal tissues will determine the total dose of radiolabeled antibody that can be given and this will be influenced by the choice of both the radionuclide and the antibody. The reported enhanced effectiveness of RIT may be due to multiple factors including selective targeting of cells responsible for tumor volume doubling, tumor surface binding rather than homogeneous binding throughout the tumor volume, targeting of the tumor vasculature, or block of cell cycle progression inG2. During RIT, there is less time for reoxygenation of hypoxic tumor cells than during a course of conventional external beam radiotherapy. It has not yet been determined whether this will have a detrimental effect on RIT. Probably the most important factor in the success of RIT is dose heterogeneity. Any viable portion of a tumor that is not targeted and does not receive a significant radiation dose will potentially lead to treatment failure, no matter how high the dose received by the remainder of the tumor. Comparisons between RIT and external beam radiation have shown a wide range of relative efficacy. Tumors most likely to respond to RIT are tumors with poor repair capabilities, tumors that are susceptible to blockage in radiosensitive phases of the cell cycle, tumors that reoxygenate rapidly, and tumors that express the relevant antigen homogeneously. From a radiobiological perspective, it appears that RIT alone is unlikely to cure many tumors and that combination with other treatment modalities will be essential.
激素、生热作用和肥胖：1988 年 6 月 12 日至 16 日在美国威斯康星大学麦迪逊分校举行的第十八届 Steenbock 研讨会的会议记录
DOI：
--
发表时间：
1989
期刊：
影响因子：
--
作者：
H. Lardy;F. Stratman
通讯作者：
F. Stratman